Insulin Suppresses Transactivation by CAAT/Enhancer-binding Proteins beta  (C/EBPbeta )

SIGNALING TO p300/CREB-BINDING PROTEIN BY PROTEIN KINASE B DISRUPTS INTERACTION WITH THE MAJOR ACTIVATION DOMAIN OF C/EBPbeta *

Shaodong GuoDagger §, Stephen B. CichyDagger , Xiaowei HeDagger , Qunying Yang, Maria Ragland, Asish K. GhoshDagger ||, Peter F. Johnson**, and Terry G. UntermanDagger DaggerDagger

From the Dagger  University of Illinois at Chicago College of Medicine and Veterans Affairs Chicago Health Care System, Chicago, Illinois 60612, the  Research Genetics, Huntsville, Alabama 35801, and the ** Eukaryotic Transcriptional Regulation Section, Regulation of Cell Growth Laboratory, NCI, Frederick Cancer Research and Development Center, Frederick, Maryland 20892-0822

Received for publication, September 19, 2000, and in revised form, December 8, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

CAAT/enhancer-binding proteins (C/EBPs) play an important role in the regulation of gene expression in insulin-responsive tissues. We have found that a complex containing C/EBPbeta interacts with an insulin response sequence in the insulin-like growth factor-binding protein-1 (IGFBP-1) gene and that a C/EBP-binding site can mediate effects of insulin on promoter activity. Here, we examined mechanisms mediating this effect of insulin. The ability of insulin to suppress promoter activity via a C/EBP-binding site is blocked by LY294002, a phosphatidylinositol 3-kinase inhibitor, but not by rapamycin, which blocks activation of p70S6 kinase. Dominant negative phosphatidylinositol 3-kinase and protein kinase B (PKB) block the effect of insulin, while activated PKB suppresses promoter function via a C/EBP-binding site, mimicking the effect of insulin. Coexpression studies indicate that insulin and PKB suppress transactivation by C/EBPbeta , but not C/EBPalpha , and that N-terminal transactivation domains in C/EBPbeta are required. Studies with Gal4 fusion proteins reveal that insulin and PKB suppress transactivation by the major activation domain in C/EBPbeta (AD II), located between amino acids 31 and 83. Studies with E1A protein indicate that interaction with p300/CBP is required for transactivation by AD II and the effect of insulin and PKB. Based on a consensus sequence, we identified a PKB phosphorylation site (Ser1834) within the region of p300/CBP known to bind C/EBPbeta . Mammalian two-hybrid studies indicate that insulin and PKB disrupt interactions between this region of p300 and AD II and that Ser1834 is critical for this effect. Signaling by PKB and phosphorylation of Ser1834 may play an important role in modulating interactions between p300/CBP and transcription factors and mediate effects of insulin and related growth factors on gene expression.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

CAAT/enhancer-binding proteins (C/EBPs)1 play an important role in the regulation of gene expression in insulin-responsive tissues (1, 2). Studies in cell culture and with knockout mice indicate that C/EBPalpha and C/EBPbeta both contribute to the regulation of hepatic glucose production (3-5), including the multihormonal regulation of phosphoenolpyruvate carboxykinase (PEPCK) (6-10), a rate-limiting enzyme for gluconeogenesis. We have reported that a nucleoprotein complex containing C/EBPbeta interacts with oligonucleotide probes containing insulin response sequences (IRSs) from the insulin-like growth factor-binding protein-1 (IGFBP-1) and PEPCK genes (11). This complex interacts with the IRS in a sequence-specific fashion that correlates with the ability of the IRS to mediate effects of insulin on promoter activity, and replacing the IRS with a consensus C/EBP-binding site in reporter gene constructs maintains the effect of insulin (11). Together, these results suggest that signaling to C/EBP proteins may contribute to the effects of insulin on gene expression via an IRS. Based on these observations, we examined specific mechanisms by which insulin may suppress promoter activity via C/EBP proteins.

Previous studies have shown that insulin inhibits basal activity of the IGFBP-1 promoter via an IRS, and that this effect of insulin is mediated by protein kinase B (PKB) downstream from phosphatidylinositol 3'-kinase (PI 3-kinase) (12). Activated PKB is translocated to the nucleus where it may interact with nuclear targets directly involved in the regulation of gene expression (13). PKB has been shown to phosphorylate and suppress transactivation by a subset of forkhead transcription factors, including FKHR, FKHRL1, and AFX (14-16). Since a nucleoprotein complex containing C/EBPbeta interacts with IRSs in the IGFBP-1 and PEPCK genes, we considered the possibility that C/EBP proteins also might contribute to the ability of insulin to regulate promoter activity downstream from PI 3-kinase and PKB.

Mink et al. (17) have reported that N-terminal transactivation domains in C/EBPbeta interact with p300/CBP coactivator proteins, and that this interaction is critical for transactivation by C/EBPbeta . GST pull-down and two-hybrid studies revealed that C/EBPbeta interacts with residues 1752-1859 of p300 (17). This region of p300/CBP also interacts with a number of other factors known to be important in the regulation of gene expression, including E1A (18), PCAF (19, 20), TFIIB (21), cyclin E-Cdk2 kinase (22), pp90Rsk (23), SV40 large T antigen (24), c-Jun (25), c-Fos (26), MyoD (27), YY1 (28), Ets-1 (29), the glucocorticoid receptor (30), and forkhead proteins (31). Since p300/CBP proteins are important for transactivation by C/EBPbeta , we considered the possibility that insulin signaling via PKB may modify interactions between this region of p300/CBP and C/EBPbeta .


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Plasmid Constructs-- The SauI/HgaI fragment of the IGFBP-1 promoter which extends 320 base pairs 5' from the RNA cap site was cloned into pGL2 (Promega) (BP1.Luc) and modified to create the Delta IRS.1, Delta IRS.1M, and Delta C/EBP reporter gene constructs, as previously reported (11, 12). The pAlb(DEI)4 reporter gene construct (32) contains 4 copies of a naturally occurring C/EBP-binding site placed immediately upstream from the albumin minimal promoter, and the pG5e1b construct consists of 5 Gal4-binding sites introduced immediately upstream of the e1b minimal promoter. Expression vectors for C/EBP proteins and fusion proteins containing the Gal4 DNA-binding domain have been described (32). Expression vectors for 12S E1A and Delta E1A, where amino acids 2-36 are deleted, were provided by Dr. Pradip Raychaudhuri (33). The Delta p85 expression vector was provided by Dr. M. Kasuga (34). Vectors expressing kinase-defective (Lys179-PKB) and constitutively active, myristoylated PKB (Myr-PKB) were provided by Dr. Thomas Franke (35). Mammalian expression vectors for CHOP and CHOP-LZ- were provided by Dr. David Ron (36).

Site-directed Mutagenesis of p300 and Creation of Fusion Proteins-- The full-length p300 cDNA was provided by Dr. David Livingston (37). The region coding for amino acids 1752-1859 region was amplified by polymerase chain reaction with one primer which contains an XhoI site (5'-CAGCTCGAGACCATGGGGATCCTCAATTGCTCACTGCCATCCTGC-3') and a second primer (5'-GGCTCTAGACTAAGTTGGTGTCGTTGGAGTGGCAGGAG-3') which contains a stop codon and an XbaI site. This fragment was cloned into the XhoI/XbaI site in pAlter.Max vector (Promega) and single stranded DNA was prepared with helper phage for site-directed mutagenesis. A BamHI site was introduced at the 5' end of this fragment and Ser1834 was replaced with alanine or aspartate by site-directed mutagenesis using the following oligonucleotides: p300.BamHI, 5'-P-CAGCGGCGGCGGGGATCCCCGGCGGGTGCTGC-3'; S1834A, 5'-P-CACACCAGTCCGCTGCATGGCGGCCATCCTCCTGCGAAG-3'; S1834D, 5'-P-CACACCAGTCCGCTGCATGTCGGCCATCCTCCTGCGAAG- 3'. The sequences of the polymerase chain reaction product and its mutations were confirmed by DNA sequencing in the University of Illinois at Chicago DNA Sequencing Center.

BamHI-XbaI fragments coding for amino acids 1752-1859 of p300 with/without mutation of Ser1834 were subcloned in-frame with the VP16 activation domain in the pVP16 eukaryotic expression vector (CLONTECH). A copy of the SV40 nuclear localization signal has been introduced in-frame with the VP16 activation domain in this vector by the manufacturer to ensure that expressed proteins are transported to the nucleus. Using a NotI site in the pAlter polylinker, BamHI-NotI fragments also were excised and cloned in-frame with glutathione S-transferase (GST) in pGEX4T-3 (Amersham Pharmacia Biotech). pGEX4T-3 vectors were introduced into pBL21RIL bacteria (Stratagene) and fusion proteins were induced at 30 °C with isopropyl-1-thio-beta -D-galactopyranoside. Cells were harvested by centrifugation and lysed by sonication, and lysates were cleared by centrifugation.

In Vitro Kinase Studies-- For kinase studies with synthetic peptides, a peptide containing residues 1826-1842 of p300 (QMLRRRMASMQRTGVVG) was synthesized, purified by high performance liquid chromatography, and analyzed by mass spectroscopy at the UIC Protein Synthesis Center. A peptide (RPRAATF) derived from a known PKB phosphorylation site in glycogen-synthase kinase-3 was purchased from Upstate Biotechnology, Inc. HepG2 cells were transfected with expression vectors for HA-tagged Myr-PKB and Myr-Lys179-PKB, and tagged proteins were immunoprecipitated with monoclonal anti-HA antibodies (Calbiochem) and protein G-Sepharose (Amersham Pharmacia Biotech), as before (12). Beads were washed and then incubated with target peptides for 10 min at 30 °C with [gamma -32P]ATP (Amersham Pharmacia Biotech) using buffers and peptide inhibitors of PKA and calcium-dependent kinase provided with the Akt kinase kit (Upstate Biotechnology, Inc.). Kinase reactions were terminated by heating at 100 °C for 5 min, and phosphorylation was measured by scintillation counting after spotting onto p81 phosphocellulose discs and washing with phosphoric acid, as before (12).

For phosphorylation studies with GST-p300 fusion proteins, bacterial lysates containing ~3 µg of fusion protein were incubated with 25 µl of a 50% slurry of washed glutathione-agarose beads (Amersham Pharmacia Biotech). Washed beads were equilibrated with 50 µl of kinase buffer containing 0.25 units of active PKBalpha , provided by Dr. P. Cohen. Phosphorylation reactions were initiated at 30 °C by the addition of [gamma -32P]ATP and terminated 20 min later by addition of 5 × Laemmli sample buffer and heating at 100 °C. Samples were cleared by centrifugation and loaded for 4-20% gradient SDS-polyacrylamide gel electrophoresis. Gels were stained with Coomassie Blue, then dried and phosphoproteins identified by autoradiography at -70 °C with enhancing screens.

Cell Culture, Transfection, and Reporter Gene Analysis-- HepG2 cells in 60-mm dishes were transfected in triplicate with calcium phosphate precipitates containing reporter gene and expression vectors together with appropriate amounts of empty vector, as previously reported (12, 14). Cells were refed with Dulbecco's modified Eagle's medium plus 1 g/liter fatty acid-free bovine serum albumin (Sigma) with/without 100 nM recombinant human insulin (Sigma) and/or 50 µM LY294002 (Calbiochem) or 200 nM rapamycin (Sigma) 18 h prior to the preparation of lysates and analysis of luciferase activity (12).


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Insulin inhibits promoter activity in luciferase reporter gene constructs containing an IRS (CAAAACA; Delta IRS.1) or when the IRS is replaced by a consensus binding site for C/EBP proteins (TTGCGCAA; Delta C/EBP), but not when the IRS is replaced by an unrelated sequence (Delta IRS.1M) (Fig. 1). This indicates that the ability of insulin to suppress promoter activity is sequence-specific and can be mediated by either an IRS or C/EBP site.



View larger version (36K):
[in this window]
[in a new window]
 
Fig. 1.   Effect of insulin and PKB on promoter activity. HepG2 cells were transfected with calcium phosphate precipitates of plasmid DNA (15 µg/dish), including 1 µg of luciferase reporter gene constructs containing a single IRS (CAAAACA; Delta IRS.1), a consensus C/EBP-binding site (TTGCGCAA; Delta C/EBP), or an unrelated sequence (Delta IRS.1M), with/without vectors expressing dominant negative PI 3-kinase (Delta p85) (5 µg), kinase-defective Lys179-PKB (10 µg), or constitutively active PKB (Myr-PKB) (1 µg) plus appropriate amounts of empty vector. Cells were refed with serum-free medium with/without 100 nM insulin, 50 µM LY294002, and/or 200 nM rapamycin and lysates prepared 18 h later. Luciferase activity is expressed relative to control and presented as the mean ± S.E. for at least three experiments performed in triplicate.

Previous studies have shown that the ability of insulin to inhibit promoter activity via an IRS is mediated through the PI 3-kinase/PKB signaling pathway (12), and we asked whether signaling to C/EBP proteins also might occur through this pathway. As shown in Fig. 1, treatment with LY294002, a specific inhibitor of PI 3-kinase, or coexpression of a dominant negative form of PI 3-kinase (Delta p85) blocks the ability of insulin to suppress promoter activity via either an IRS or C/EBP-binding site (Fig. 1), indicating that this effect of insulin also is PI 3-kinase-dependent. Treatment with rapamycin, which blocks the activation of p70S6 kinase downstream from PI 3-kinase, does not disrupt the ability of insulin to inhibit promoter activity. Coexpression of a kinase-deficient form of PKB (Lys179-PKB), which blocks the activation of PKB in HepG2 cells (12), disrupts the ability of insulin to inhibit promoter activity. Expression of constitutively active PKB (Myr-PKB) inhibits promoter activity of reporter gene constructs containing either an IRS (Delta IRS.1) or a C/EBP-binding site (Delta C/EBP), but not an unrelated sequence (Delta IRS.1M), mimicking the effect of insulin. Together, these results indicate that signaling via PKB can mediate effects of insulin on promoter activity via either an IRS or C/EBP-binding site.

To determine whether endogenous C/EBP proteins are required for the ability of insulin to inhibit promoter activity via a C/EBP-binding site, we performed coexpression studies with CHOP. CHOP, a C/EBP family member which contains a leucine zipper dimerization domain but no functional DNA-binding domain, disrupts the ability of endogenous C/EBP proteins to form hetero- or homodimers that are capable of binding to canonical C/EBP sites (11, 36). In contrast, CHOP does not prevent C/EBPbeta from interacting with other nuclear proteins and forming a complex with an IRS (11). As shown in Fig. 2, overexpression of CHOP blocks the ability of insulin and Myr-PKB to inhibit promoter activity via a C/EBP-binding site in the Delta C/EBP construct (solid bars). This effect of CHOP is specific, since CHOP does not disrupt other effects of insulin and Myr-PKB in these cells, including the ability to suppress promoter function via an IRS in the Delta IRS.1 construct (open bars). CHOP-LZ-, which is missing the leucine zipper dimerization domain, does not block the ability of insulin and Myr-PKB to suppress promoter function via a C/EBP-binding site, indicating that this effect of CHOP is mediated through interaction with endogenous proteins via its leucine zipper domain. Together, these results indicate that interaction with hetero- or homodimers of C/EBP proteins is necessary for the ability of insulin and PKB to suppress promoter activity via this C/EBP-binding site.



View larger version (22K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of CHOP. HepG2 cells were transfected with 10 µg/dish of plasmid DNA, including 1 µg of the Delta C/EBP (solid bar) or Delta IRS.1 (open bar) reporter gene construct with/without expression vectors for CHOP or CHOP-LZ- (5 µg) and/or Myr-PKB (1 µg). Cells were refed with serum-free medium with/without insulin, and harvested for analysis of luciferase activity 18 h later.

To determine whether insulin and PKB suppress promoter activity when specific C/EBP proteins occupy this C/EBP-binding site, we performed co-transfection studies with expression vectors for C/EBPalpha and C/EBPbeta . As shown in the left panel of Fig. 3A, C/EBPalpha and full-length C/EBPbeta (C/EBPbeta 1-276) effectively stimulate promoter activity in the Delta C/EBP construct. This effect is disrupted when the C/EBP site is replaced by an unrelated sequence (Delta IRS.1M), indicating that it is mediated through the C/EBP site. Truncated C/EBPbeta (C/EBPbeta 132-276), which is missing two N-terminal transactivation domains, is less effective in stimulating promoter activity and this residual effect is not disrupted when the C/EBP-binding site is replaced by an unrelated sequence (Delta IRS.1M). These results confirm that C/EBPalpha and full-length C/EBPbeta stimulate promoter activity via the C/EBP-binding site and that N-terminal activation domains are required for sequence-specific transactivation by C/EBPbeta .



View larger version (36K):
[in this window]
[in a new window]
 
Fig. 3.   Effects of C/EBP proteins. A, Delta C/EBP reporter gene construct. Left panel, effect of C/EBP proteins on promoter activity. HepG2 cells were transfected with 10 µg/dish plasmid DNA, including 1 µg of either the Delta C/EBP (solid bars) or Delta IRS.1M (open bar) reporter gene construct, plus 5 µg of vector expressing C/EBPalpha , and either full-length (C/EBPbeta 1-276) or truncated (C/EBPbeta 132-276) C/EBPbeta plus empty vector. Cells were refed with serum-free medium 18 h prior to harvest. Right panel, HepG2 cells were transfected with 10 µg/dish plasmid DNA, including 1 µg of the Delta C/EBP construct together with 5 µg of vector expressing C/EBPalpha , C/EBPbeta 1-276, or C/EBPbeta 132-276 with/without 1 µg of Myr-PKB expression vector. Cells were refed with serum-free medium with/without insulin 18 h prior to harvest and analysis of luciferase activity. B, pAlb(DEI)4 reporter gene construct. Cells were transfected with 10 µg/dish plasmid DNA, including 1 µg of the pAlb(DEI)4 reporter gene construct with/without 5 µg of vector expressing C/EBPalpha , C/EBPbeta 1-276, or C/EBPbeta 132-276, and/or 1 µg of Myr-PKB. Cells were refed with serum-free medium with/without insulin 18 h prior to harvest.

As shown in the right panel of Fig. 3A, coexpression of C/EBPalpha disrupts the ability of insulin and PKB to suppress promoter activity in the Delta C/EBP construct. In contrast, insulin and PKB suppress the ability of full-length C/EBPbeta (C/EBPbeta 1-276) to stimulate promoter activity. This effect of insulin and PKB is disrupted when the N-terminal region of C/EBPbeta is deleted (C/EBPbeta 132-276). These results indicate that insulin and PKB suppress transactivation by C/EBPbeta , but not C/EBPalpha , and that the N-terminal region of C/EBPbeta is required for this effect.

We performed similar studies using a reporter gene construct where an array of 4 naturally occurring C/EBP-binding sites has been placed immediately upstream of the minimal albumin promoter (pAlb[DEI]4). In contrast to the Delta C/EBP construct, insulin modestly stimulates basal activity of the pAlb(DEI)4 promoter, possibly reflecting effects which are mediated via other transcription factors that can interact with this naturally occurring C/EBP-binding site or with other parts of this construct. As shown in Fig. 3B, overexpression of C/EBPalpha or C/EBPbeta stimulates the activity of this artificial promoter construct and truncated C/EBPbeta is less effective. Insulin and PKB suppress the ability of C/EBPbeta to stimulate the activity of this artificial construct. In contrast, neither C/EBPalpha nor truncated C/EBPbeta confers this effect of insulin and PKB, confirming that insulin and PKB suppress transactivation by C/EBPbeta , but not C/EBPalpha , and that the N-terminal region of C/EBPbeta is required for this effect.

We next examined which regions of C/EBPbeta are involved in mediating the effect of insulin and PKB on transactivation. For these experiments, we expressed fusion proteins containing the Gal4 DNA-binding domain (which contains its own nuclear localization signal) in-frame with portions of C/EBPbeta , or the activation domain of VP16 as a control. Transactivation was measured using the pG5e1b luciferase reporter gene construct, which contains 5 Gal4-binding sites immediately 5' to the e1b minimal promoter and has negligible basal activity in HepG2 cells.

Fig. 4A indicates the location of the leucine zipper dimerization domain (LZ), DNA-binding domain, and the two N-terminal transactivation domains previously identified in C/EBPbeta (AD I and II) (32). As shown in Fig. 4B, the Gal 4 fusion protein containing full-length C/EBPbeta stimulates the pG5e1b promoter. Transactivation is enhanced when the C-terminal region containing the leucine zipper and DNA-binding domain is removed from C/EBPbeta (Gal4.beta 1-132), and transactivation is increased still further when an additional 39 amino acids are removed (Gal4.beta 1-83), consistent with previous studies (32). The N-terminal region of C/EBPbeta contains two activation domains, which are located between amino acids 1-31 (AD I) and 31-83 (AD II). The Gal4.beta 31-83 fusion protein is more potent in stimulating promoter activity than the Gal4.beta 1-31 protein, consistent with previous studies indicating that the major activation domain in C/EBPbeta is located between amino acids 31 and 83 (32).



View larger version (28K):
[in this window]
[in a new window]
 
Fig. 4.   Gal4 fusion proteins. A, structure of C/EBPbeta . The location of the leucine zipper dimerization domain (LZ) is located C-terminal to the DNA-binding domain (DBD) and two N-terminal activation domains (AD I and II) in C/EBPbeta are shown. B, transactivation by Gal4 fusion proteins. HepG2 cells were co-transfected with vectors expressing fusion proteins containing the Gal4 DNA-binding domain (hatched box) in-frame with the activation domain of VP16 or portions of C/EBPbeta together with the pG5e1b reporter gene construct. Cells were refed with serum-free medium 18 h prior to lysis and analysis of luciferase activity. Luciferase activity in cells transfected with the pG5e1b vector alone was similar to background (<200 relative luminescence units). C, effects of insulin and PKB. Cells were transfected with the pG5e1b construct and vectors expressing Gal4 fusion proteins with/without 1 µg of the Myr-PKB expression vector, then refed with serum-free medium with/without 100 nM insulin 18 h before harvest and analysis of luciferase activity.

As shown in Fig. 4C, insulin and PKB suppress transactivation by Gal4.beta 1-276 but not Gal4.VP16, indicating that this effect of insulin and PKB is specific. Insulin and PKB also suppress transactivation by Gal4.beta 1-132 and Gal4.beta 1-83, indicating that regions outside the N-terminal transactivation domains of C/EBPbeta are not required for this effect of insulin and PKB. Insulin and PKB suppress transactivation by Gal4.beta 31-83 (AD II) but do not suppress transactivation by Gal4.beta 1-31 (AD I), indicating that this effect is specific for ADII.

Previous studies have shown that p300/CBP coactivator proteins interact directly with the N-terminal region of C/EBPbeta (17). As shown in the left panel of Fig. 5A, coexpression of E1A, an adenovirus protein that binds and sequesters p300/CBP, disrupts transactivation by the Gal4.beta 1-132 fusion protein in a dose-dependent fashion. In contrast, coexpression of Delta E1A, which does not interact with p300/CBP but still binds retinoblastoma protein and related proteins (33, 38), does not suppress transactivation by the Gal4.beta 1-132 fusion protein but actually enhances this effect. Together, these results indicate that interaction with p300/CBP is critical for transactivation by this region of C/EBPbeta , and that other cellular proteins that can interact with Delta E1A may repress this function, similar to results obtained with other transcription factors (39).2



View larger version (30K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of E1A on transactivation and insulin and PKB action. A, effect on Gal4.beta 1-132. Left panel, dose-response study. HepG2 cells were transfected with calcium phosphate precipitates containing 15 µg/dish plasmid DNA, including 1 µg of pG5e1b and 0.3 µg of the Gal4.beta 1-132 expression vector together with 0, 0.3, 1, 3, or 10 µg of a vector expressing 12S E1A or 10 µg of a vector expressing Delta E1Amut, which does not bind p300/CBP. Cells were refed with serum-free medium 18 h prior to harvest. Right panel, E1A disrupts effects of insulin and PKB. HepG2 cells were transfected with the pG5e1b reporter gene construct and the Gal4.beta 1-132 expression vector with/without 10 µg of vector expressing E1A or Delta E1A protein and/or 1 µg of the Myr-PKB expression vector. Cells were refed with serum-free medium with/without insulin 18 h prior to harvest. B, effects of E1A on activation domain I and II. Left panel, effect of E1A on transactivation. Cells were co-transfected with the pG5e1b reporter gene construct (1 µg) together with expression vectors for the Gal4.beta 31-83 (solid bar) or Gal4.beta 1-31 (open bar) (0.3 µg) with/without 10 µg of vector expressing E1A or Delta E1A and appropriate amounts of empty vector. Right panel, cells were transfected the pG5e1b reporter gene construct together with expression vectors for Gal4.beta 31-83 (0.3 µg), E1A or Delta E1A protein (10 µg), and/or Myr-PKB (1 µg) as indicated. Cells were refed with serum-free medium with/without insulin 18 h prior to harvest.

As shown in the right panel of Fig. 5A, coexpression of E1A (but not Delta E1A) also disrupts the ability of insulin and PKB to suppress transactivation by the Gal4.beta 1-132 fusion protein. Together, these results suggest that interaction with p300/CBP is required for effective transactivation by the N-terminal region of C/EBPbeta and for the inhibitory effect of insulin and PKB.

As shown in the left panel of Fig. 5B, E1A (but not Delta E1A) also suppresses transactivation by AD II of C/EBPbeta (Gal4.beta 31-83), but not AD I (Gal4.beta 1-31), indicating that interaction with p300/CBP is required for transactivation by AD II, but not AD I. As shown in the right panel of Fig. 5B, E1A (but not Delta E1A) disrupts the ability of insulin and PKB to suppress transactivation by Gal4.beta 31-83, indicating that interaction with p300/CBP is required for insulin and PKB to suppress transactivation by AD II.

Previous studies have shown that C/EBPbeta interacts directly with residues 1752-1859 of p300 and that this interaction involves the N-terminal region of C/EBPbeta that contains ADII (17). As shown in Fig. 6A, this region of p300/CBP, which includes a portion of a cysteine/histidine-rich domain (CH3) and the adjacent glutamine-rich domain (Q), also interacts with a number of other trans-acting factors that contribute to the regulation of gene expression (18-31).



View larger version (24K):
[in this window]
[in a new window]
 
Fig. 6.   Structure of p300/CBP. A, interaction domains in p300/CBP. The region within p300/CBP that interacts with C/EBPbeta is underlined. Other trans-acting factors that interact with this region and/or other domains within p300/CBP also are shown. B, predicted PKB phosphorylation site. The consensus sequence for PKB phosphorylation sites (RXRXX(S/T)) and its relationship to the sequence flanking Ser1834 in human p300 is shown. This predicted PKB site is conserved in human and mouse CBP. The sequence for this region of mouse p300 has not been reported (N/A).

Based on a consensus sequence for PKB phosphorylation sites (Arg-Xaa-Arg-Xaa-Xaa-Ser/Thr) (40), we identified a putative PKB phosphorylation site in this region of human p300 (Ser1834). This PKB site is conserved in both human and mouse CBP (Fig. 6B), suggesting that it may be physiologically important. The sequence for this region of mouse p300 has not been reported. We did not identify other PKB sites in p300, CBP, or C/EBPbeta .

Based on this observation, we asked whether this site is phosphorylated by PKB and is required to disrupt interactions between this region of p300 and AD II. As shown in Fig. 7A, activated PKB (but not kinase-defective PKB) phosphorylates a synthetic peptide containing amino acids 1826 through 1842 of human p300 and this phosphorylation is similar to the level achieved with a peptide derived from glycogen-synthase kinase-3, a known substrate for PKB. As shown in Fig. 7B, PKB also phosphorylates a bacterially expressed recombinant fusion protein containing amino acids 1752-1859 of p300 in-frame with GST (GST-p300), but not GST alone. This phosphorylation is blocked when Ser1834 is replaced by either alanine (GST.p300(S/A)) or aspartate (GST.p300(S/D)), confirming that Ser1834 is a target for phosphorylation by PKB in vitro.



View larger version (32K):
[in this window]
[in a new window]
 
Fig. 7.   Phosphorylation of Ser1834 by PKB. A, synthetic peptides. HA-tagged, constitutively active, myristoylated PKB (Myr-PKB) and kinase-deficient, myristoylated PKB (Myr-Lys179-PKB) were expressed in HepG2 cells, then bound to Sepharose beads by immunoprecipitation with anti-HA monoclonal antibody and incubated with synthetic peptides containing amino acids 1826-1842 of human p300 (p300) or a peptide containing a known PKB phosphorylation site derived from glycogen-synthase kinase-3 (GSK3). The incorporation of 32P into phosphopeptide was determined by scintillation counting after spotting on phosphocellulose discs, as described under "Experimental Procedures." B, GST.p300 fusion proteins. GST and fusion proteins containing GST in-frame with amino acids 1752-1859 of p300 (GST.p300) with/without mutation of Ser1834 to alanine (GST.p300(S/A)) or aspartate (GST.p300(S/D)) were expressed in bacteria, then bound to glutathione-Sepharose beads prior to incubation with/without activated PKB and [gamma -32P]ATP for 20 min at 30 °C. Phosphorylation reactions were terminated and glutathione-bound fusion proteins were eluted by the addition of Laemmli sample buffer and heating at 100 °C. Proteins were loaded for 4-20% SDS-polyacrylamide gel electrophoresis, then stained with Coomassie Blue (lower panel) and 32P-labeled proteins were identified in dried gels by autoradiography (upper panel).

To examine interactions between this portion of p300 and C/EBPbeta , we next performed mammalian two-hybrid studies in HepG2 cells. As shown in Fig. 8A, coexpression of a fusion protein containing amino acids 1752-1859 of p300 in-frame with the VP16 activation domain enhances the ability of the Gal4.beta 1-132 fusion protein to stimulate luciferase activity in HepG2 cells transfected with the pG5e1b reporter gene construct in a dose-dependent fashion. No effect is seen when the VP16 activation domain is expressed alone, indicating that this effect is mediated through interaction with this region of p300. The VP16.p300 fusion protein also enhances transactivation by the Gal4.beta 32-83 fusion protein (Fig. 8B), but does not enhance transactivation by Gal4.beta 1-31 (data not shown), indicating that this region of p300 interacts with AD II, but not AD I in cells.



View larger version (33K):
[in this window]
[in a new window]
 
Fig. 8.   Interaction of p300 and C/EBPbeta : mammalian two-hybrid assay. A, interaction of Gal4.beta 1-132 with VP16.p300 in HepG2 cells. Cells were transfected with 15 µg/dish plasmid DNA including 1 µg of the pG5e1b reporter gene construct, 0.3 µg of the Gal4.beta 1-132 expression vector and 0, 0.3, 1, 3, or 10 µg of the vector expressing the activation domain of VP16 in-frame with amino acids 1752-1859 of p300 (VP16.p300) or 10 µg of the vector expressing the VP16 activation domain alone. Cells were refed with serum-free medium 18 h before lysis. B, suppression of transactivation by insulin and PKB. Left panel, HepG2 cells were transfected with the pG4e1b reporter gene construct and the Gal4.beta 1-132 expression vector together with 3 µg of vector expressing VP16.p300 (solid bars), VP16.p300(S/D) (open bars), or VP16.p300(S/A) (hatched bars) with/without 1 µg of the Myr-PKB expression vector. Cells were refed with serum-free medium with/without 100 nM insulin 18 h before harvest and analysis of luciferase activity. Right panel, HepG2 cells were transfected with the pG5e1b reporter gene construct and Gal4.beta 31-83 expression vector together with vectors expressing VP16.p300, VP16.p300(S/D), VP16.p300(S/A), and Myr-PKB constructs, then refed with serum-free medium with/without insulin 18 h prior to harvest.

We next examined whether insulin and PKB disrupt the interaction between this region of p300 and C/EBPbeta , and whether the phosphorylation of Ser1834 is required for this effect of insulin and PKB. As shown in Fig. 8B, coexpression of VP16.p300 enhances transactivation by the Gal4.beta 1-132 fusion protein (left panel) and Gal4.beta 31-83 (right panel) without disrupting the ability of insulin and PKB to suppress transactivation. This result indicates that signaling via insulin and PKB disrupts interaction between this region and ADII of C/EBPbeta in cells.

Replacing Ser1834 with aspartate, a negatively charged amino acid (VP16.p300(S/D)) blocks the ability of insulin and PKB to suppress interaction between this region of p300 and ADII in cells, but does not impair the ability of the fusion protein with interact with ADII in two-hybrid studies. This result supports the concept that phosphorylation of Ser1834 is critical for the effect of insulin and PKB, and suggests that this effect of insulin and PKB is not mediated simply by introducing a negative charge at this site. Replacing Ser1834 with alanine, a neutral amino acid that is not susceptible to phosphorylation, also blocks the ability of insulin and PKB to disrupt interaction between this region of p300 and ADII, supporting the concept that phosphorylation at this site is required for the effect of insulin and PKB. Replacing Ser1834 with alanine partially reduces the ability of this fusion protein to interact with ADII in the two-hybrid assay (Fig. 8B), supporting the concept that Ser1834 is important for interaction between this region of p300 and ADII.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

C/EBPbeta plays an important role in the regulation of gene expression in the liver, mammary gland, and adipose, hematopoietic and reproductive tissues (41-45). We recently found that a nucleoprotein complex containing C/EBPbeta interacts with insulin response sequences in the IGFBP-1 and PEPCK genes and that a consensus C/EBP-binding site confers effects of insulin on promoter activity, similar to an IRS (11). Based on these findings, we asked whether insulin may suppress transactivation by specific C/EBP family members and examined mechanisms mediating this effect of insulin.

Studies with pharmacological inhibitors and with constitutively active and dominant negative forms of PI 3-kinase and PKB revealed that PI 3-kinase plays a critical role in mediating effects of insulin on promoter activity via a C/EBP-binding site and that signaling via PKB can mediate this effect of insulin. Previous studies have shown that signaling via PI 3-kinase-dependent pathways mediates effects of insulin on hepatic expression of IGFBP-1, PEPCK, and glucose-6-phosphatase genes (12, 46-48) and we have reported that insulin suppresses basal IGFBP-1 promoter activity through an IRS via events that are mediated by PKB downstream from PI 3-kinase (12). Recent studies indicate that PKB can mediate effects of insulin on promoter activity via the phosphorylation of FKHR, FKHRL1, or AFX, a subgroup of the forkhead/winged-helix family of transcription factors which contain several PKB phosphorylation sites (14, 15, 16, 49). The results of the present study indicate that signaling via PI 3-kinase and PKB also can disrupt transactivation by C/EBPbeta and, thereby, suppress promoter activity by a mechanism that is independent of forkhead transcription factors.

This effect of insulin appears to be selective, since insulin and PKB suppressed transactivation by C/EBPbeta , but not C/EBPalpha . We found that insulin and PKB suppress transactivation by the major activation domain in C/EBPbeta , located between residues 31 and 83. It is interesting to note that the corresponding region of C/EBPalpha contains an insertion of 12 amino acids that are not present in AD II of C/EBPbeta (50). It is possible that these additional residues may alter the function of this activation domain, including the ability of insulin and PKB to regulate interactions with coactivator proteins required for transactivation. Also, C/EBPalpha contains another activation domain which is not present in C/EBPbeta (50) and which may not be susceptible to regulation by insulin and PKB. In addition, regions outside the activation domains have been found to contribute to functional differences between C/EBPalpha and C/EBPbeta (32, 51) and also might contribute to differences in the effects of insulin and PKB on transactivation by full-length C/EBPalpha and C/EBPbeta .

Previous studies have shown that extracellular stimuli can alter the phosphorylation of several sites in C/EBPbeta , and modify their effects on promoter activity. Calcium-regulated phosphorylation of Ser276 in the leucine zipper domain of C/EBPbeta results in enhanced transactivation (52), as does Ras-dependent phosphorylation of Thr235, and the phosphorylation of Ser105 by protein kinase A (53, 54) or pp90Rsk (55). Phosphorylation by protein kinase C of Ser240 in the DNA-binding domain of C/EBPbeta reduces transactivation by interfering with DNA binding (54). Our studies with Gal4 fusion proteins indicate that phosphorylation at these sites is not required for the ability of insulin and PKB to suppress transactivation by C/EBPbeta . Instead, we find that insulin and PKB suppress the function of the major C/EBPbeta activation domain by disrupting interactions with p300/CBP proteins. To our knowledge, this report provides the first evidence for an effect of insulin or PKB that is mediated through the modification of a nuclear coactivator, in this case p300/CBP.

In this context, it is important to note that other kinases also may contribute to this effect of insulin. PKB, like other members of the AGC kinase family, is activated by the phosphorylation of a conserved hydrophobic activation loop by phosphatidylinositoldependent kinase-1 (56, 57). We found that overexpression of a kinase-deficient form of PKB, which blocks the activation of PKB in HepG2 cells (12), disrupts the ability of insulin to suppress transactivation by C/EBPbeta . It is possible that overexpression of kinase-deficient PKB, which may interfere with the ability of phosphatidylinositol-dependent kinase-1 to phosphorylate and activate PKB, also may block the activation of other AGC kinases downstream from phosphatidylinositoldependent kinase-1. As recently reviewed, several of these kinases can phosphorylate sites that are similar to the consensus motif for PKB, including serum- and glucocorticoid-inducible kinase (glycogen-synthase kinase-3), pp90Rsk, and p70S6 kinase (56, 58). Preliminary studies indicate that pp90Rsk and p70S6 kinase also can phosphorylate Ser1834 in vitro, but not as efficiently as PKB.3 Additional studies will be required to determine whether other AGC kinases also contribute to signaling to Ser1834 in vivo.

To explore the possibility that phosphorylation of Ser1834 is required to disrupt interactions between p300 and C/EBPbeta , we performed mammalian two-hybrid studies with VP16.p300 fusion proteins where this residue was altered. Replacing Ser1834 with either aspartate or alanine disrupts the ability of insulin and PKB to suppress interaction between this domain and ADII in cells, indicating that this site is critical for the effect of insulin and PKB. Interestingly, replacing Ser1834 with alanine, a neutral amino acid, reduces the ability of VP16.p300 fusion proteins to interact with ADII in two-hybrid studies, while introducing aspartate, a negatively charged amino acid, is neutral in this assay. Preliminary studies indicate that replacing Ser1834 with alanine also partially reduces the ability of GST fusion proteins containing this region of p300 to bind C/EBPbeta in in vitro pull-down binding assays, while placing an aspartate residue at this location does not alter C/EBPbeta binding either positively or negatively,3 similar to the results of two-hybrid assays. These results support the concept that Ser1834 is important for the ability of this region of p300 to interact with C/EBPbeta , and indicate that this interaction is not altered simply by introducing a negative charge at this site.

Previous studies have shown that phosphorylation can modify protein function by multiple mechanisms, and the introduction of a negative charge is not always sufficient to mimic the effect of phosphorylation. For example, phosphorylation of Ser133 in CREB results in the recruitment of p300/CBP, and replacing this residue with aspartate does not reproduce that effect (59). Based on the results of the present study, it is possible that phosphorylation of Ser1834 may recruit other proteins to this site in p300 and, thereby, block interactions with ADII. Nakajima et al. (23) have reported that insulin treatment causes pp90Rsk to associate with this region of p300/CBP. Additional studies will be required to determine whether phosphorylation of Ser1834 is sufficient to alter interactions between p300/CBP and AD II of C/EBPbeta , or whether the recruitment of other proteins (including pp90Rsk) is required for this effect.

p300/CBP can interact with multiple proteins at the same time via distinct domains and, thereby, mediate cooperative effects of transcription factors on gene expression (60, 61). Cooperative interactions involving C/EBPbeta are important for the ability of thyroid hormone, glucocorticoids, and cAMP to stimulate the PEPCK promoter (8, 10), and a complex containing C/EBPbeta can interact with IRSs which function cooperatively to enhance effects of glucocorticoids on activity in the IGFBP-1 and PEPCK promoters (11, 62, 63). C/EBP proteins appear to play an important role in mediating effects of insulin on stimulated PEPCK promoter activity that are independent of an IRS (9), and overexpressing a fragment of p300/CBP that contains the C/EBPbeta -binding domain disrupts the ability of insulin to suppress PEPCK gene expression in cAMP-stimulated hepatoma cells (23). Based on the present study, it is interesting to speculate that signaling to this region of p300/CBP may contribute to the ability of insulin or related growth factors to suppress promoter activity by disrupting cooperative interactions involving C/EBPbeta .

In this context, it is important to note that this region of p300 (1752-1859) also interacts with other factors that are known to be important in the regulation of gene expression. Nasrin et al. (31) recently reported that DAF-16, a forkhead protein in Caenorhabditis elegans, interacts with this region and the KIX (CREB binding) domain of p300/CBP (31), and pull-down studies indicate that FKHR, a mammalian homologue of DAF-16, also interacts with these regions of p300/CBP.3 It will be important to determine whether signaling to p300/CBP may contribute to the ability of insulin to suppress the function of the C-terminal transactivation domain of these forkhead proteins (64).

As recently reviewed, several lines of evidence suggest that p300/CBP proteins play an important role in the regulation of the cell cycle and cell survival (65). C/EBP proteins have important effects on the proliferation of hepatocytes (55), and the region of p300/CBP that binds C/EBPbeta (17) also interacts with other factors that are involved in the regulation of cellular growth and differentiation, including E1A (18), cyclin E-Cdk2 kinase (22), pp90Rsk (23), SV40 large T antigen (24), c-Jun (25), c-Fos (26), MyoD (27), YY1 (28), and Ets-1 (29). Based on these observations and the results of the present study, it will be important to examine the role that signaling through PI 3-kinase and PKB to this region of p300/CBP plays in mediating effects of insulin and related growth factors on cellular proliferation and differentiation, and metabolism.


    ACKNOWLEDGEMENTS

We gratefully acknowledge Dr. Andrew Paterson, University of Dundee, for expression and activation of PKBalpha , and Drs. Philip Cohen and Graham Rena for helpful suggestions and advice.


    FOOTNOTES

* This work was supported in part by National Institutes of Health, NIDDK, Grant DK41430 and the Department of Veterans Affairs Merit Review Program.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Present address: Lexicon Genetics, 4000 Research Forest Dr., The Woodlands, TX 77381-4287.

|| Present address: Section of Rheumatology (M/C 733), Dept. of Medicine, University of Illinois at Chicago, 900 South Ashland Ave., Chicago, IL 60607.

Dagger Dagger To whom all correspondence should be addressed: Rm. 5A122A Research (MP 151), Veterans Affairs Chicago Health Care System (West Side), 820 South Damen Ave., Chicago, IL 60612. Tel.: 312-666-6500 (ext. 57427); Fax: 312-455-5877; E-mail: unterman@uic.edu.

Published, JBC Papers in Press, December 14, 2000, DOI 10.1074/jbc.M008542200

2 A. K. Ghosh, unpublished observations.

3 S. Guo and T. Unterman, unpublished observations.


    ABBREVIATIONS

The abbreviations used are: C/EBP, CAAT/enhancer-binding protein; CRE, cAMP response element; GST, glutathione S-transferase; IGFBP-1, insulin-like growth factor-binding protein-1; IRS, insulin response sequence; PEPCK, phosphoenolpyruvate carboxykinase; PKB, protein kinase B; PI 3-kinase, phosphatidylinositol 3'-kinase; CBP, CREB-binding protein; Myr, myristoylated; LZ, leucine zipper.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Mandrup, S., and Lane, M. D. (1997) J. Biol. Chem. 272, 5367-5370[Free Full Text]
2. Darlington, G. J., Wang, N., and Hanson, R. W. (1995) Curr. Opin. Genet. Dev. 5, 565-570[CrossRef][Medline] [Order article via Infotrieve]
3. Lee, Y.-H., Sauer, B., Johnson, P. F., and Gonzalez, F. J. (1997) Mol. Cell. Biol. 17, 6014-6022[Abstract]
4. Liu, S., Croniger, C., Arizmendi, C., Harada-Shiba, M., Ren, J., Poli, V., Hanson, R. W., and Friedman, J. E. (1999) J. Clin. Invest. 103, 207-213[Abstract/Free Full Text]
5. Croniger, C., Trus, M., Lysek-Stupp, K., Cohen, H., Liu, Y., Darlington, G. J., Poli, V., Hanson, R. W., and Reshef, L. (1997) J. Biol. Chem. 272, 26306-26312[Abstract/Free Full Text]
6. Roesler, W. J., Crosson, S. M., Vinson, C., and McFie, P. J. (1996) J. Biol. Chem. 271, 8060-8074
7. Park, E. A., Roesler, W. J., Liu, J., Klemm, D. J., Gurney, A. L., Thatcher, J. D., Shuman, J., Friedman, A., and Hanson, R. (1990) Mol. Cell. Biol. 10, 6264-6272[Medline] [Order article via Infotrieve]
8. Yamada, K., Duong, D. T., Scott, D. K., Wang, J. C., and Granner, D. K. (1999) J. Biol. Chem. 274, 5880-5887[Abstract/Free Full Text]
9. Yeagley, D., Moll, J., Vinson, C. A., and Quinn, P. G. (2000) J. Biol. Chem. 275, 17814-17820[Abstract/Free Full Text]
10. Park, E. A., Song, S., Vinson, C., and Roesler, W. J. (1999) J. Biol. Chem. 274, 211-217[Abstract/Free Full Text]
11. Ghosh, A. K., Lacson, R., Liu, P., Cichy, S. B., Danilkovich, A., Guo, S., and Unterman, T. G. (2000) J. Biol. Chem. 276, 8507-8515[Abstract/Free Full Text]
12. Cichy, S. B., Uddin, S., Danilkovich, A., Guo, S., Klippel, A., and Unterman, T. G. (1998) J. Biol. Chem. 273, 6482-6487[Abstract/Free Full Text]
13. Andjelkovic, M., Alessi, D. R., Meier, R., Fernandez, A., Lamb, N. J. C., Frech, M., Cron, P., Cohen, P., Lucocq, J. M., and Hemmings, B. A. (1997) J. Biol. Chem. 272, 31515-31524[Abstract/Free Full Text]
14. Guo, S., Rena, G., Cichy, S., He, X., Cohen, P., and Unterman, T. (1999) J. Biol. Chem. 274, 17184-17192[Abstract/Free Full Text]
15. Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., and Greenberg, M. E. (1999) Cell 96, 857-868[Medline] [Order article via Infotrieve]
16. Kops, G. J., de Ruiter, N. D., Vries-Smits, A. M., Powell, D. R., Bos, J. L., and Burgering, B. M. (1999) Nature 398, 630-634[CrossRef][Medline] [Order article via Infotrieve]
17. Mink, S., Haenig, B., and Klempnauer, K.-H. (1997) Mol. Cell. Biol. 17, 6609-6617[Abstract]
18. Arany, Z., Newsome, D., Oldread, E., Livingston, D. M., and Eckner, R. (1995) Nature 374, 81-84[CrossRef][Medline] [Order article via Infotrieve]
19. Korzus, E., Torchia, J., Rose, D. W., Xu, L., Kurokawa, R., McInerney, E. M., Mullen, T. M., Glass, C. K., and Rosenfeld, M. G. (1998) Science 279, 703-707[Abstract/Free Full Text]
20. Yang, X.-J., Ogryzko, V. V., Nishikawa, J., Howard, B. H., and Nakatani, Y. (1996) Nature 382, 319-324[CrossRef][Medline] [Order article via Infotrieve]
21. Chrivia, J. C., Kwok, R. P. S., Lamb, N., Hagiwara, M., Montminy, M. R., and Goodman, R. H. (1993) Nature 365, 855-859[CrossRef][Medline] [Order article via Infotrieve]
22. Felzien, L. K., Farrell, S., Betts, J. C., Mosavin, R., and Nabel, G. J. (1999) Mol. Cell. Biol. 19, 4241-4246[Abstract/Free Full Text]
23. Nakajima, T., Fukamizu, A., Takahashi, J., Gage, F. H., Fisher, T., Blenis, J., and Montminy, M. R. (1996) Cell 86, 465-474[Medline] [Order article via Infotrieve]
24. Eckner, R., Ludlow, J. W., Lill, N. L., Oldread, E., Arany, Z., Modjtahedi, N., DeCaprio, J. A., Livingston, D. M., and Morgan, J. A. (1996) Mol. Cell. Biol. 16, 3454-3464[Abstract]
25. Lee, J., See, R. H., Deng, T., and Shi, Y. (1996) Mol. Cell. Biol. 16, 4312-4326[Abstract]
26. Bannister, A. J., and Kouzarides, T. (1995) EMBO J. 14, 4758-4762[Abstract]
27. Sartorelli, V., Huang, J., Hamamori, Y., and Kedes, L. (1997) Mol. Cell. Biol. 17, 1010-1026[Abstract]
28. Lee, J., See, R. H., Galvin, K. M., Wang, J., and Shi, Y. (1995) Nucleic Acids Res. 23, 925-931[Abstract]
29. Yang, C., Shapiro, L. H., Rivera, M., Kumar, A., and Brindle, P. K. (1998) Mol. Cell. Biol. 18, 2218-2229[Abstract/Free Full Text]
30. Sheppard, K. A., Phelps, K. M., Williams, A. J., Thanos, D., Glass, C. K., Rosenfeld, M. G., Gerritsen, M. E., and Collins, T. (1998) J. Biol. Chem. 273, 29291-29294[Abstract/Free Full Text]
31. Nasrin, N., Ogg, S., Cahill, C. M., Biggs, W., Nui, S., Dore, J., Calvo, D., Shi, Y., Ruvkun, G., and Alexander-Bridges, M. C. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10412-10417[Abstract/Free Full Text]
32. Williams, S. C., Baer, M., Dillner, A. J., and Johnson, P. F. (1995) EMBO J. 14, 3170-3183[Abstract]
33. Raychaudhuri, P., Bagchi, S., Devoto, S. H., Kraus, V. B., Moran, E., and Nevins, J. R. (1991) Genes Dev. 5, 1200-1211[Abstract]
34. Hara, K., Yonezawa, K., Sakaue, H., Ando, A., Kotani, K., Kitamura, T., Kitamura, Y., Ueda, H., Stephens, L., Jackson, T. R., Hawkins, P. T., Dhand, R., Clark, A. E., Holman, G. D., Waterfield, M. D., and Kasuga, M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7415-7419[Abstract]
35. Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D. R., and Greenberg, M. E. (1997) Science 275, 661-665[Abstract/Free Full Text]
36. Ron, D., and Habener, J. F. (1992) Genes Dev. 6, 439-453[Abstract]
37. Eckner, R., Ewen, M. E., Newsome, D., Gerdes, M., DeCaprio, J. A., Lawrence, J. B., and Livingston, D. M. (1994) Genes Dev. 869-884
38. Dyson, N., and Harlow, E. (1992) Cancer Surv. 12, 161-195[Medline] [Order article via Infotrieve]
39. Pouponnot, C., Jayaraman, L., and Massague, J. (1998) J. Biol. Chem. 273, 22865-22868[Abstract/Free Full Text]
40. Alessi, D. R., Caudwell, F. B., Andjelkovic, M., Hemmings, B. A., and Cohen, P. (1996) FEBS Lett. 399, 333-338[CrossRef][Medline] [Order article via Infotrieve]
41. Johnson, P. F., and Williams, S. C. (1994) in Liver Gene Expression (Tronche, F. , and Yaniv, M., eds) , pp. 232-257, R. G. Landes Co., Austin, TX
42. Cao, Z., Umek, R. M., and McKnight, S. L. (1991) Genes Dev. 5, 1538-1552[Abstract]
43. Screpanti, I., Romani, L., Musiani, P., Modesti, A., Fattori, E., Lazzaro, D., Sellitto, C., Scarpa, S., Bellavia, D., Lattanzio, G., Bistoni, F., Frati, L., Cortese, R., Gulino, A., Ciliberto, G., Costantini, F., and Poli, V. (1995) EMBO J. 14, 1932-1941[Abstract]
44. Robinson, G. W., Johnson, P. F., Hennighausen, L., and Sterneck, E. (1998) Genes Dev. 12, 1907-1916[Abstract/Free Full Text]
45. Sterneck, E., Tessarollo, L., and Johnson, P. F. (1997) Genes Dev. 11, 2153-2162[Abstract/Free Full Text]
46. Sutherland, C., O'Brien, R. M., and Granner, D. K. (1995) J. Biol. Chem. 270, 15501-15506[Abstract/Free Full Text]
47. Dickens, M., Svitek, C. A., Culbert, A. A., O'Brien, R. M., and Tavare, J. M. (1998) J. Biol. Chem. 273, 20144-20149[Abstract/Free Full Text]
48. Schmoll, D., Walker, K. S., Alessi, D. R., Grempler, R., Burchell, A., Guo, S., Walther, R., and Unterman, T. G. (2000) J. Biol. Chem. 275, 36324-36333[Abstract/Free Full Text]
49. Biggs, W. H., III, Meisenhelder, J., Hunter, T., Cavenee, W. K., and Arden, K. C. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 7421-7426[Abstract/Free Full Text]
50. McKnight, S. L. (1992) in Transcriptional Regulation (McKnight, S. L. , and Yamamoto, K. R., eds) , pp. 771-795, Cold Spring Harbor Press, Cold Spring Harbor, NY
51. Lee, Y.-H., Williams, S. C., Baer, M., Sterneck, E., Gonzalwz, F. J., and Johnson, P. F. (1997) Mol. Cell. Biol. 17, 2038-2047[Abstract]
52. Wegner, M., Cao, Z., and Rosenfeld, M. G. (1992) Science 256, 370-373[Medline] [Order article via Infotrieve]
53. Nakajima, T., Kinoshita, S., Sasagawa, T., Sasaka, K., Naruto, M., Kishimoto, T., and Akira, S. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2207-2211[Abstract]
54. Trautwein, C., van der, G. P., Karin, M., Hunter, T., and Chojkier, M. (1994) J. Clin. Invest. 93, 2554-2561[Medline] [Order article via Infotrieve]
55. Buck, M., Poli, V., van der Geer, P. T., Chojkier, M., and Hunter, T. (1999) Mol. Cell. 4, 1087-1092[Medline] [Order article via Infotrieve]
56. Vanhaesebroeck, B., and Alessi, D. R. (2000) Biochem. J. 346, 561-76[CrossRef][Medline] [Order article via Infotrieve]
57. Belham, C., Wu, S., and Avruch, J. (1999) Curr. Biol. 9, 93-96[CrossRef][Medline] [Order article via Infotrieve]
58. Kandel, E. S., and Hay, N. (1999) Exp. Cell. Res. 253, 210-29[CrossRef][Medline] [Order article via Infotrieve]
59. Gonzalez, G. A., and Montminy, M. R. (1989) Cell 59, 675-80[Medline] [Order article via Infotrieve]
60. Goldman, P. S., Tran, V. K., and Goodman, R. H. (1997) Res. Prog. Horm. Res. 52, 103-120[Medline] [Order article via Infotrieve]
61. Kamei, Y., Lan, X., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S.-C., Heyman, R. A., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. (1996) Cell 85, 403-414[Medline] [Order article via Infotrieve]
62. Unterman, T. G., Fareeduddin, A., Harris, M. A., Goswami, R. G., Porcella, A., Costa, R. H., and Lacson, R. G. (1994) Biochem. Biophys. Res. Commun. 203, 1835-4194[CrossRef][Medline] [Order article via Infotrieve]
63. Imai, E., Stromstedt, P. E., Quinn, P. G., Carlstedt-Duke, J., Gustafsson, J. A., and Granner, D. K. (1990) Mol. Cell Biol. 10, 4712-4719[Medline] [Order article via Infotrieve]
64. Tomizawa, M., Kumar, A., Perrot, V., Nakae, J., Accili, D., Kumaro, A., and Rechler, M. (2000) J. Biol. Chem. 275, 7289-7295[Abstract/Free Full Text]
65. Giordano, A., and Avantaggiati, M. L. (1999) J. Cell. Physiol. 181, 218-230[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.